Tumor necrosis factor inhibitors (TNFi) are frequently used first line in rheumatoid arthritis (RA) patients; and a new analysis shows that repeat use of TNFi dominates over the use of non-TNFi biologics when the initial TNFi therapy has failed. https://t.co/hmFZKrMdJ1 https://t.co/whCPvAAMMi